Qsymia set for US launch and Belviq waits out classification as Contrave CV trial speeds ahead
This article was originally published in Scrip
Executive Summary
Orexigen Therapeutics reported on 5 September that it has achieved faster than anticipated patient enrolment in the cardiovascular outcomes trial (CVOT) requested by the US FDA earlier this year for the San Diego-based company's Contrave (naltrexone SR/bupropion SR), which could indicate strong patient demand for weight loss drugs generally, according to at least one equity analyst that follows competitors in the obesity market.